Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients

International Clinical Psychopharmacology

Volumn 22, Issue 1, 2007, Pages 21-27

  Hori, Hikaru ^a   Yoshimura, Reiji ^a   Yamada, Yasuhisa ^a   Ikenouchi, Atsuko ^a   Mitoma, Masae ^a   Ida, Yoshishige ^b   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b National Hospital Organization   (Japan)

Author keywords

3 methoxy 4 hydroxyphenylglycol; Brain derived neurotrophic factor; Cytokines; Homovanillic acid; Olanzapine; Schizophrenia

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; BRAIN DERIVED GROWTH FACTOR; CATECHOLAMINE; CYTOKINE; HOMOVANILLIC ACID; INTERLEUKIN 2; INTERLEUKIN 6; OLANZAPINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOLAMINES; CYTOKINES; FEMALE; HOMOVANILLIC ACID; HUMANS; INTERLEUKIN-2; INTERLEUKIN-6; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845615926     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3280103593     Document Type: Article

References (32)

1. Alonso R, Chaudieu I, Diorio J, Krishnamurthy A, Quirion R, Boksa P, et al. (1993). Interleukin-2 modulates evoked release of [3H]dopamine in rat cultured mesencephalic cells. J Neurochem 61:1284-1290.
2. Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, Delapp NW, Wong DT, Moore NA, et al. (1997). In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry 58 (Suppl 10):28-36.
3. Davidson M, Kahn RS, Warne P, et al. (1991). Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Arch Gen Psychiatry 48:73-76.
4. Davidson M, Kahn RS, Stern RG, et al. (1993). Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res 46:151-163.
5. Denicoff KD, Rubinow DR, Papa MZ, et al. (1987). The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 107:293-300.
6. Goto M, Yoshimura R, Kakihara S, et al. (2006). Risperidone in the treatment of psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry 30:1701-1706.
7. Green AI, Tsuang MT, Schildkraut JJ (1997). Catecholamines, their metabolites, and response to typical and atypical neuroleptics: toward an understanding of the mechanisms of action of neuroleptic drugs. In: Friedhoff AJ, Amin F, editors. Plasma homovanillic acid in schizophrenia. Washington, District of Columbia: American Psychiatric Press. pp. 61-78.
8. Kakihara S, Yoshimura R, Shinkai K, et al. (2005). Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 20:71-78.
9. Kim Y-K, Kim L, Lee M-S (2000). Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 44:165-175.
10. Kim D-J, Kim W, Yoon S-J, et al. (2001). Effect of risperidone on serum cytokines. Int J Neurosci 111:11-19.
11. Lapchak PA (1992). A role for IL-2 in the regulation of striatal dopaminergic function. Neuroreport 3:165-168.
12. Li XM, Perry KW,Wong DT, Bymaster FP, et al. (1998). Olanzapine increases in vivo dopamine and noradrenaline release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology 136:153-161.
13. Lieberman JA, Tollefson G, Tohen M, et al. (2003). Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160:1396-1404.
14. Maes M, Bosmans E, Calabrese J, Smith R, Meller HY, et al. (1995). Interleukin-2, and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. Psychiatry Res 29:141-152.
15. Minegishi A, Ishizaki T (1984). Determination of free 3-methoxy-4-hydroxyphenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric detection. J Chromatogr 311:51-57.
16. Monteleone P, Fabrazzo M, Tortorella A, Maj M, et al. (1997). Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 71:11-17.
17. Petitto JM, McCarthy DB, Rinker CM, Huang Z, Getty T, et al. (1997). Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2. J Neuroimmunol 73:183-190.
18. Pirildar S, Gonul AS, Taneli F, Akdeniz T, et al. (2004). Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 28:709-713.
19. Schuld A, Kraus T, Haack M, Hinze-Selah D, Kuhn M, Pollmacher T, et al. (2000). Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine. Schizophr Res 43:164-166.
20. Shimizu E, Hashimoto K, Watanabe H, et al. (2003). Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett 351:111-114.
21. Tan YL, Zhou DF, Cao LY, Zoir YZ, Zhang XY, et al. (2005). Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 382:27-32.
22. Tollefson GD, Sanger TM (1997). Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154:466-474.
23. Tollefson GD, Beasley CM Jr, Tran PV, et al. (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154:457-465.
24. Toyooka K, Asama K, Watanabe Y, et al. (2002). Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 110:249-257.
25. Yeung PKF, Buckley SL, Pedder SCJ, Dingmanse J, et al. (1996). Determination of 3,4-dihydroxyphenylacetic acid and 5-hydroxyindoleacetic acid in human plasma by a simple and rapid high-performance liquid chromatography assay. J Pharm Sci 85:451-453.
26. Yoshimura R, Nakamura J, Ueda N, Terao T, et al. (2000a). Effect of risperidone on plasma free3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement. Int Clin Psychopharmacol 15:175-180.
27. Yoshimura R, Yanagihara N, Hara K, et al. (2000b). Inhibitory effects of clozapine and other antipsychotic drugs on noradrenaline transporters in cultured bovine adrenal medullary cells. Psychopharmacology 149:17-23.
28. Yoshimura R, Ueda N, Shinkai K, Nakamura J, et al. (2003). Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. Int Clin Psychopharmacol 18:107-111.
29. Yoshimura R, Nakamura J, Shinkai K, Ueda N (2004). Clinical response to antidepressant treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review. Prog Neuropsychopharmacol Biol Psychiatry 28:611-616.
30. Yoshimura R, Shinkai K, Toyohira Y, et al. (2005a). Effects of zotepine and olanzapine on noradrenaline transporter in cultured bovine adrenal medullary cells. Hum Psychopharmacol Clin Exp 20:477-484.
31. Yoshimura R, Nakamura J, Shinkai K, et al. (2005b). An open study of risperidone liquid in the acute phase of schizophrenia. Hum Psychopharmacol Clin Exp 20:243-248.
32. Yukimasa T, Yoshimura R, Tamagawa A, et al. (2006). High-frequency repetitive transcranial magnetic stimulation improves refractory depression via influencing catecholamine and brain-derived neurotrophic factors. Pharmacopsychiatry 39:52-59.